Exhibiting at VIV Asia 2025

Boehringer Ingelheim Singapore Pte. Ltd. – Innovating Healthcare for Humans and Animals

Boehringer Ingelheim Singapore Pte. Ltd. is the Singapore-based subsidiary of Boehringer Ingelheim, a global leader in pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a history spanning more than 130 years, Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies, operating in over 130 countries. The Singapore entity serves as a key regional hub for human pharmaceuticals, animal health, and contract biopharmaceutical manufacturing.

Core Business and Specialization

Boehringer Ingelheim specializes in three key areas:

• Human Pharmaceuticals – Prescription medicines targeting cardiovascular, respiratory, metabolic, and central nervous system diseases.
• Animal Health – Innovative vaccines and therapeutics for livestock and companion animals.
• Biopharmaceutical Contract Manufacturing – Providing cutting-edge development and production services to third-party pharmaceutical and biotech companies.

Boehringer Ingelheim's Singapore operations play a critical role in research, production, and regional distribution, strengthening its footprint in the Asia-Pacific healthcare market.

Product Portfolio

Boehringer Ingelheim Singapore offers a broad range of pharmaceutical and veterinary solutions, designed to improve human and animal health.

• Human Pharmaceuticals

  • Cardiovascular & Metabolic Diseases – Treatments for hypertension, diabetes, and stroke prevention (Jardiance®, Trajenta®, Micardis®).
  • Respiratory Diseases – Leading therapies for asthma and COPD (Spiriva®, Ofev®, Striverdi®).
  • Central Nervous System Disorders – Medications for Alzheimer’s and Parkinson’s disease.

• Animal Health

  • Livestock Solutions – Vaccines and therapeutics for poultry, swine, and cattle (Ingelvac®, Bovela®, Vaxxitek®).
  • Companion Animal Care – Treatments for pet health, parasite control, and immunization (NexGard®, HeartGard®, Frontline®).

• Biopharmaceutical Contract Manufacturing

  • State-of-the-art production services for monoclonal antibodies, cell and gene therapy, and recombinant proteins.
  • Clients include top global pharmaceutical and biotech firms.

Research & Development: Advancing Scientific Innovation

Boehringer Ingelheim is a research-driven company, investing €4.6 billion annually in R&D to develop breakthrough pharmaceutical and veterinary solutions.

Key R&D focus areas:

• mRNA technology and gene therapy for personalized medicine.
• Immuno-oncology and precision medicine for cancer treatment.
• Antimicrobial resistance solutions for sustainable livestock farming.
• AI-driven drug discovery and biopharmaceutical process optimization.

Global Market Presence & Singapore Operations

Boehringer Ingelheim has a strong presence in over 130 countries, with Singapore serving as a key regional hub for Asia-Pacific healthcare operations.

• Singapore’s advanced biopharmaceutical manufacturing capabilities support regional supply chain demands.
• Strategic partnerships with local research institutions and biotech firms to drive innovation.
• Investments in regional production facilities to enhance pharmaceutical and veterinary product distribution.

Certifications & Regulatory Compliance

Boehringer Ingelheim maintains high regulatory standards, ensuring product safety, efficacy, and compliance.

• EU-GMP Certified Biopharmaceutical Manufacturing
• ISO 9001:2015 Quality Management
• Good Manufacturing Practices (GMP) for Pharmaceuticals & Veterinary Products
• HACCP & Global Animal Health Compliance Standards

These certifications reinforce Boehringer Ingelheim’s commitment to quality and regulatory excellence.

Financial Performance & Growth

Boehringer Ingelheim reported €25.3 billion in global revenue (2023), with Asia-Pacific contributing significantly to business growth. The company’s strategic expansion in Singapore is driven by:

• Rising demand for chronic disease treatments in the region.
• Growth in pet healthcare and livestock farming solutions.
• Increased outsourcing of biopharmaceutical production.

Export & Biopharma Manufacturing Records

Boehringer Ingelheim Singapore is a key contributor to the company’s biopharma contract manufacturing business, producing therapeutic proteins, monoclonal antibodies, and viral vaccines.

• Expansion in contract manufacturing partnerships with biotech firms.
• Growing export volumes of pharmaceutical and veterinary products across Asia-Pacific.
• Singapore facility recognized as a center for biopharma innovation.

Customer Testimonials & Industry Recognition

Boehringer Ingelheim is recognized by healthcare professionals, veterinarians, and biotech partners for:

• Industry-leading innovations in cardiology, respiratory, and metabolic diseases.
• High-efficacy animal health vaccines improving livestock productivity.
• Trusted biopharmaceutical manufacturing partner for next-generation therapeutics.

The company has received numerous awards for innovation, sustainability, and corporate responsibility, including:

• Top 10 Global Pharma Companies for R&D Investment.
• Sustainability Leadership Award in Animal Health.
• Best Biopharmaceutical Contract Manufacturer (Asia-Pacific).

Conclusion

With cutting-edge research, a strong commitment to innovation, and a growing presence in Asia-Pacific, Boehringer Ingelheim Singapore Pte. Ltd. continues to transform healthcare for humans and animals. The company’s scientific advancements, global collaborations, and investments in next-generation biopharmaceuticals position it as a leading force in healthcare innovation.